期刊文献+

卒中后抑郁患者事件相关电位与单胺类神经递质水平相关性研究 被引量:10

Relationship between event-related potential and the serum levels of monoamine neurotransmitter in patients with post-stroke depression
原文传递
导出
摘要 目的探讨卒中后抑郁患者事件相关电位(event-related potential,ERP)与单胺类神经递质的关系。方法测定48例卒中后抑郁患者(PSD组)和46例体检健康者(对照组)ERP和血浆单胺类神经递质水平,并进行比较分析。结果 PSD组ERP测定异常率为91.7%,ERP中N2及P3波潜伏期较对照组延长,P3波幅较对照组降低(P<0.01);PSD组去甲肾上腺素、多巴胺和5-羟色胺水平较对照降低(P<0.01);PSD组ERP成分中P3波潜伏期与去甲肾上腺素、多巴胺和5-羟色胺水平呈负相关(P<0.05),P3波幅与去甲肾上腺素、多巴胺和5-羟色胺水平呈正相关(P<0.05)。结论卒中后抑郁患者存在血浆单胺类神经递质水平降低与认知障碍,且二者相互影响,ERP和血浆单胺类神经递质水平测定可作为卒中后抑郁患者临床诊治的判定指标。 Objective To explore the relationship between event-related potential (ERP) and the serum levels of monoamine neurotransmitter in patients with post-stroke depression (PSD). Methods ERP and the serum levels of monoamine neurotransmitter test were detected and compared in 48 patients with PSD (PSD group) and 46 normal controls (control group). Results The abnormal rate of ERP was 91. 7~ in PSD group. The latency of N2 and P3 of ERP were prolonged and the amplitude of P3 was lower in PSD group in comparison with control group (P^0.01). The serum levels of monoamine neurotransmitter (noradrenalin, dopamine and 5 HT) were significantly lower in PSD group than those in control group (P^0.01). The latency of P3 of ERP was negatively correlated with the levels of noradrenalin, dopamine and 5-HT (P%0.05), and P3 amplitude was positively correlated with the levels of noradrenalin, dopamine and 5-HT (P%0.01) in PSD group. Conclusion The serum levels of rnonoamine neurotransmitter and cognitive dysfunction decrease in PSD patients, and the two indexes are interacting. ERP and the serum levels of monoamine neurotransmitter test can be used as clinical diagnosis and treatment indexes for PSD patients.
出处 《中华实用诊断与治疗杂志》 2012年第12期1177-1179,共3页 Journal of Chinese Practical Diagnosis and Therapy
基金 河南省卫生厅医学科技攻关项目(200803083 201203100)
关键词 卒中后抑郁 事件相关电位 单胺类神经递质 Post stroke depression event related potential monoamine neurotransmitter
  • 相关文献

参考文献14

二级参考文献85

共引文献107

同被引文献114

  • 1孙安阳,李德兴.肾血管性高血压大鼠脑室注射γ-氨基丁酸的心血管效应(英文)[J].中国药理学报,1994,15(2):136-138. 被引量:4
  • 2孙玉华,邹飒枫,许晶.卒中后抑郁的神经生物学异常[J].国外医学(脑血管疾病分册),2005,13(9):710-712. 被引量:2
  • 3Sharon Turban,Paul J Thuluvath,Mohamed G Atta.Hepatorenal syndrome[J].World Journal of Gastroenterology,2007,13(30):4046-4055. 被引量:14
  • 4Roman G C, Salloway S, Black S E, etal. Randomized, placebo controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size[J]. Stroke, 2010,41(6) : 1213-1221.
  • 5Kavirajan H, Schneider L S. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia; a meta analysis of randomised controlled trials[J]. Lancet Neurol, 2007,6(9) ; 782-792.
  • 6Dichgans M, Markus H S, Salloway S, et al. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL[J]. Lancet Neurol, 2008,7(4) :310-318.
  • 7Erkinjuntti T, Kurz A, Gauthier S, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial[J]. Lancet, 2002,359(9314):1283- 1290.
  • 8Ballard C, Sauter M, Scheltens P, et al. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia; the Vantage study[J]. Curr Med Res Opin, 2008,24(9);2561-2574.
  • 9Wilcock G, Mobius H J, Stoffler A. A double blind, placebocontrolled multicentre study of memantine in mild to moderate vascular dementia ( MMM500 ) [ J ]. Int Clin Psychopharmacol, 2002,17 (6) : 297-305.
  • 10Meyer J S, Judd B W, Tawaklna T, et al. Improved cognition after control of risk factors for multi- infarct dementia [ J ]. JAMA,1986,256(16) :2203-2209.

引证文献10

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部